Christopher Paluch

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Combination Therapy

Endoplasmic Reticulum Stress

Top Venues

Immunotherapy advances

Nature immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Martin Fellermeyer, Consuelo Anzilotti, Christopher Paluch, Richard J Cornall, Simon J Davis, Uzi Gileadi
Combination CD200R/PD-1 blockade in a humanised mouse model. Immunotherapy advances 3 (1) (2023)
Alan Kennedy, Erin Waters, Behzad Rowshanravan, Claudia Hinze, Cayman Williams, Daniel Janman, Thomas Andrew Fox, Claire Booth, Anne Maria Pesenacker, Neil Halliday, Blagoje Soskic, Satdip Kaur, Omar S Qureshi, Emma Catherine Morris, Shinji Ikemizu, Christopher Paluch, Jiandong Huo, Simon J Davis, Emmanuel Boucrot, Lucy Sarah Kate Walker, David Michael Sansom
Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nature immunology 23 (9) (2022)